Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword.
Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy. maria.troiano@uniba.it
Maria
M
Trojano
D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D002185:Cannabidiol; D063386:Cannabinoid Receptor Agonists / Q000627:therapeutic use; D063385:Cannabinoid Receptor Modulators / Q000627:therapeutic use*; D013759:Dronabinol; D004338:Drug Combinations; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D009128:Muscle Spasticity / Q000209:etiology / Q000517:prevention & control*; D010936:Plant Extracts / Q000627:therapeutic use
D018726:Anti-Dyskinesia Agents; D063386:Cannabinoid Receptor Agonists; D063385:Cannabinoid Receptor Modulators; D004338:Drug Combinations; D015507:Drugs, Investigational; D010936:Plant Extracts; D002185:Cannabidiol; D013759:Dronabinol; C587251:nabiximols